Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Despite high enthusiasm, early attempts to develop clinical treatments based on animal research with neurotrophins were not successful. Here we survey clinical trials with neurotrophins, compared with neurotrophic factors of other gene families, and delineate the most likely reasons for their failure. We then suggest improved methods for regulated local supply of NTs to specific populations of neurons and discuss future therapeutic procedures evolving from the more detailed knowledge of the signal transduction pathways activated by neurotrophins via their receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since the discovery of BDNF and its receptor TrkB, efforts have been made to use BDNF as a therapeutic agent for neuropsychiatric disorders or to develop small-molecule pharmaceuticals that could increase the production of BDNF or activate TrkB in brain (for review, see99,100), and these efforts are still ongoing101.”
From Neuronal plasticity and neurotrophic factors in drug responses (2017) · cites this paper as [99]
In the citing paper
“A lack of methods for effectively and safely delivering growth factors to the nervous system over sustained time periods has been a major factor limiting their translational testing32.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [32]
Citations
Cites
Exercise: a behavioral intervention to enhance brain health and plasticity
Cotman, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02143-4 · Cited by 2,739 · cited 1×
“New, therapeutically interesting perspectives evolved from the observation that physical exercise evokes a marked increase in BDNF levels in the rat brain, in particular in the hippocampus and cerebral corte”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundNEUROTROPHINS AND SYNAPTIC PLASTICITY
McAllister, A. K., Katz, L. C., & Lo, D. C. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.295 · Cited by 1,337 · cited 1×
“This decisive statement can be made because NTs, besides regulating survival, differentiation and maintenance of neuron-specific characteristics (for example, neurotransmitters and neuropeptides), also are important in modulating activity-dependent neuronal plasticity, essential for the functional and structural refin…”
BackgroundNerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“Although (unregulated) overexpression of neurotrophic molecules by viral vectors has already provided encouraging result”
BackgroundHuang, Z. J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., & Tonegawa, S. (1999) · Cell · doi:10.1016/s0092-8674(00)81509-3 · Cited by 1,198 · cited 1×
“For the treatment of neurons that are themselves directly involved in the formation of neuronal circuits, modified in a refined manner by neuronal activity, the local overexpression of NTs could result in functional disturbances, as for example demonstrated in the visual cortex by the local transgenic overexpression o…”
BackgroundHANDBOOK OF EXPERIMENTAL PHARMACOLOGY
Reichlin, S. (1969) · The American Journal of The Medical Sciences · doi:10.1097/00000441-196911000-00008 · Cited by 1,134
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system
Bibel, M., & Barde, Y.-A. (2000) · Genes & Development · doi:10.1101/gad.841400 · Cited by 1,065
Fischer, W., Wictorin, K., Björklund, A., Williams, L. R., Varon, S., & Gage, F. H. (1987) · Nature · doi:10.1038/329065a0 · Cited by 1,024
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Anthony Altar, C., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 788 · cited 1×
“Other members of the NT family were linked to a much broader spectrum of biological action”
Background
Research works printed but not linked: 1
- Lowenstein, P.R. & Enquist, L.W. Protocols for Gene Transfer in Neuroscience (Wiley, Chichester, UK, 1996).
Cited by
Items 101–200 of 335
7,8-Dihydroxyflavone improves memory consolidation processes in rats and mice
Bollen, E., Vanmierlo, T., Akkerman, S., Wouters, C., Steinbusch, H. M. W., & Prickaerts, J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.09.029 · Cited by 60
Motoneurons crave glial cell line-derived neurotrophic factor
Bohn, M. C. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.012 · Cited by 70
Sinha, K., Sun, C. E., Kamari, R., & Bettermann, K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.003 · Cited by 70
Kang, S. S., Keasey, M. P., Cai, J., & Hagg, T. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1746-12.2012 · Cited by 69
“However, delivery of CNTF to the CNS is hampered by limited diffusion across the blood– brain barrier and serious systemic side effects, which caused the failure of clinical trials for amyotrophic lateral sclerosis (Thoenen and Sendtner, 2002).”
BackgroundChattopadhyay, M. (2004) · Brain · doi:10.1093/brain/awh103 · Cited by 63
Bottai, D., Cigognini, D., Madaschi, L., Adami, R., Nicora, E., Menarini, M., Giulio, A. M. D., & Gorio, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.01.010 · Cited by 63
Effects of Indole Fatty Alcohols on the Differentiation of Neural Stem Cell Derived Neurospheres
Coowar, D., Bouissac, J., Hanbali, M., Paschaki, M., Mohier, E., & Luu, B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0493616 · Cited by 67
Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration
Fanara, P., Wong, P.-Y. A., Husted, K. H., Liu, S., Liu, V. M., Kohlstaedt, L. A., Riiff, T., Protasio, J. C., Boban, D., Killion, S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64575 · Cited by 59
“Survival studies and other clinical outcomes of low specificity, however, are affected by factors besides disease-modifying therapies and require large number of subjects to show effects in clinical trials (1).”
Karlsson, J., Fong, K. S. K., Hansson, M. J., Elmàr, E., Csiszar, K., & Keep, M. F. (2004) · Journal of Neurosurgery · doi:10.3171/jns.2004.101.1.0128 · Cited by 59
Viral vectors as tools to model and treat neurodegenerative disorders
Déglon, N., & Hantraye, P. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.707 · Cited by 64
“The potential of trophic factors for the treatment of neurodegenerative disorders was, for example, recognized 20 years ago, but peripheral injections or intracerebroventricular infusions of recombinant proteins were often associated with side effects [78–80,28,81,82].”
BackgroundSebastião, A. M., Assaife‐Lopes, N., Diógenes, M. J., Vaz, S. H., & Ribeiro, J. A. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.06.028 · Cited by 66
“had minimal beneficial effects and produced side effects such as pain and gastrointestinal symptoms [180].”
BackgroundViability-Dependent Promoting Action of Adult Neural Precursors in Spinal Cord Injury
Bottai, D., Madaschi, L., Giulio, A. M. D., & Gorio, A. (2008) · Molecular Medicine · doi:10.2119/2008-00077.bottai · Cited by 53
Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 71
“Although BDNF was initially proposed as a therapeutic alternative for depression, clinical trials with recombinant BDNF have failed to achieve significant antidepressant efficacy [92, 93].”
MethodUluç, K., Kendigelen, P., Fidan, E., Zhang, L., Chanana, V., Kintner, D. B., Aktüre, E., Song, C., Ye, K., Sun, D., et al. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990061 · Cited by 56
“Clinical trials using BDNF for treatment of amyotrophic lateral sclerosis, Huntington's Disease, human immunodeficiency virus related neuropathy and other neurological diseases have been universally disappointing [15].”
MethodQuintão, N. L. M., Santos, A. R. S., Campos, M. M., & Calixto, J. Β. (2007) · Pain · doi:10.1016/j.pain.2007.06.027 · Cited by 59
“These NTFs have recently emerged as an exciting new class of potential targets for development of new drugs to control neuropathic pain (Thoenen and Sendtner, 2002; Sah et al., 2003).”
BackgroundMicroRNA-155 deletion reduces anxiety- and depressive-like behaviors in mice
Fonken, L. K., Gaudet, A. D., Gaier, K. R., Nelson, R. J., & Popovich, P. G. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.10.019 · Cited by 53
Wang, J., Hu, W., Jiang, Z., & Feng, M. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i5.323 · Cited by 55
Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration
Carrascosa, C., Torres‐Alemán, I., López-López, C., Carro, E., Espejo, L. A., Torrado, S., & Torrado, J. J. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00562-3 · Cited by 58
“While effective growth factor-based therapies are yet to be developed, implementation of new pharmaceutical preparations aimed to deliver the growth factor to target organs is actively seeked [1].”
BackgroundInfluentialElectrospun Fiber Scaffolds for Engineering Glial Cell Behavior to Promote Neural Regeneration
Puhl, D. L., Funnell, J. L., Nelson, D. W., Gottipati, M. K., & Gilbert, R. J. (2020) · Bioengineering · doi:10.3390/bioengineering8010004 · Cited by 59
Increased Extraocular Muscle Strength with Direct Injection of Insulin-like Growth Factor-I
Anderson, B. C., Christiansen, S. P., Grandt, S., Grange, R. W., & McLoon, L. K. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1416 · Cited by 52
“The patterns of expression of MyHC isoforms in EOMs in particular are extremely complex.(25) Expression patterns of these isoforms are highly adaptable and appear to change with most perturbations of the muscle.”
BackgroundBDNF Mediates Neuroprotection against Oxygen-Glucose Deprivation by the Cardiac Glycoside Oleandrin
Kanegan, M. J. V., Dong, H., Dunn, D., Yang, P., Newman, R. A., West, A. E., & Lo, D. C. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2700-13.2014 · Cited by 52
“However, the BDNF protein itself has proven problematic as a clinical agent, due to short serum half-life, poor bioavailability, minimal BBB-penetrability, and limited diffusion within CNS tissues (Thoenen and Sendtner, 2002; Longo and Massa, 2013; Lu et al., 2013).”
BackgroundTocopherol Derivative TFA-12 Promotes Myelin Repair in Experimental Models of Multiple Sclerosis
Blanchard, B., Heurtaux, T., Garcia, C., Moll, N. M., Caillava, C., Grandbarbe, L., Klosptein, A., Kerninon, C., Frah, M., Coowar, D., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-13.2013 · Cited by 51
“However, despite some promising results in experimental models, attempts to develop clinical trials based on growth factors have been mainly unsuccessful (Thoenen and Sendtner, 2002).”
ResultSconce, M. D., Churchill, M. J., Moore, C., & Meshul, C. K. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.12.080 · Cited by 53
“…pharmacokinetic profile to oral or intravenous administration (Pardridge et al., 1998; Ankeny et al., 2001; Jang et al., 2010; Nagahara and Tuszynski, 2011) and clinical trials attempting to introduce recombinant BDNF have failed (Ochs et al., 2000; Thoenen and Sendtner, 2002; Bartus et al., 2014).”
BackgroundResultSimonato, M. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.09.013 · Cited by 57
“NoTeS settings because NTFs can trigger plastic changes that remain detectable when they are no longer expressed, whereas their long-term expression may be detrimental for brain function (Thoenen and Sendtner, 2002).”
BackgroundHausott, B., & Klimaschewski, L. P. (2019) · The Anatomical Record · doi:10.1002/ar.24126 · Cited by 53
“Several clinical trials using neurotrophic factors as treatments for PNS disorders unfortunately failed (Thoenen and Sendtner, 2002).”
BackgroundNagano, M., Sakai, A., Takahashi, N., Umino, M., Yoshioka, K., & Suzuki, H. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705772 · Cited by 48
Fasting for 20 h does not affect exercise‐induced increases in circulating BDNF in humans
Gibbons, T. D., Cotter, J. D., Ainslie, P. N., Abraham, W. C., Mockett, B. G., Campbell, H. A., Jones, E. M. W., Jenkins, E. J., & Thomas, K. N. (2023) · The Journal of Physiology · doi:10.1113/jp283582 · Cited by 53
“Since pharmaceutical interventions that aim to safely deliver BDNF to the human brain have thus far failed (Gao et al., 2022; Sakane & Pardridge, 1997; Thoenen & Sendtner, 2002), it is important to tease out the mechanisms underlying endogenous BDNF production throughout healthy ageing.”
Background(2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.089540 · Cited by 47
TrkB transmembrane domain: bridging structural understanding with therapeutic strategy
Enkavi, G., Girych, M., Moliner, R., Vattulainen, I., & Castrén, E. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.02.001 · Cited by 44
Nerve conduit scaffolds for discrete delivery of two neurotrophic factors
Catrina, S., Gander, B. A., & Madduri, S. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.030 · Cited by 46
“NTFs promote neuronal survival, axonal regeneration, and Schwann cells migration [10].”
BackgroundProtection of Spiral Ganglion Neurons from Degeneration Using Small-Molecule TrkB Receptor Agonists
Yu, Q., Chang, Q., Liu, X., Wang, Y., Li, H., Gong, S., Ye, K., & Lin, X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0854-13.2013 · Cited by 52
Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor
Fletcher, J. M., & Hughes, R. A. (2006) · Journal of Peptide Science · doi:10.1002/psc.760 · Cited by 45
“Several plausible explanations have been put forward for this lack of clinical effect [32,33], at the forefront of which are concerns about the pharmacokinetic properties of BDNF.”
BackgroundFernandez, A. M., Carro, E., López-López, C., & Torres‐Alemán, I. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.05.003 · Cited by 48
Chattopadhyay, M., Mata, M. M., Goss, J. R., Wolfe, D. P., Huang, S., Glorioso, J. C., & Fink, D. J. (2007) · Diabetologia · doi:10.1007/s00125-007-0702-4 · Cited by 45
“Neurotrophin therapy for human diabetic neuropathy has not been possible, in large part because systemic administration of short-lived potent bioactive peptides to humans is limited by the effects of high doses of these peptides on cells outside the peripheral nervous system that result in intolerable or unacceptable…”
BackgroundNagano, M., Sakai, A., Takahashi, N., Umino, M., Yoshioka, K., & Suzuki, H. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705550 · Cited by 45
VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?
Lambrechts, D., Storkebaum, E., & Carmeliet, P. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.04.004 · Cited by 47
Neural interactions with materials
Dalton, P. D., & Mey, J. (2009) · Frontiers in bioscience · doi:10.2741/3277 · Cited by 49
“Consequently, neurotrophins are one class of molecules that was soon explored in clinical studies to treat neurodegenerating diseases – albeit with questionable results so far (105-106).”
BackgroundKang, S. S., Wu, Z., Liu, X., Edgington‐Mitchell, L. E., & Ye, K. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01248-1 · Cited by 47
“However, the outcomes of several clinical trials using recombinant BDNF are disappointing [17, 18].”
BackgroundAlbadrani, H. M., Chauhan, P., Ashique, S., Babu, M. A., Iqbal, D., Almutary, A. G., Abomughaid, M. M., Kamal, M., Paiva‐Santos, A. C., Alsaweed, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116376 · Cited by 53
Duffy, A. M., Schaner, M. J., Wu, S. H., Staniszewski, A., Kumar, A., Arévalo, J. C., Arancio, O., Chao, M. V., & Scharfman, H. E. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.03.008 · Cited by 43
“Another reason that therapeutics based on neurotrophins like BDNF have not been implemented is that neurotrophins are large molecules that do not diffuse readily (Thoenen and Sendtner, 2002).”
Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis
Rauskolb, S., Dombert, B., & Sendtner, M. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.04.007 · Cited by 50
Self-citationDelivery of Brain-Derived Neurotrophic Factor via Nose-to-Brain Pathway
Vaka, S. R. K., Murthy, S. N., Balaji, A., & Repka, M. A. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0572-9 · Cited by 42
“Unfortunately, all these methods lack practical clinical relevance due to the invasive nature of administration (23,24).”
Tsai, T., Klausmeyer, A., Conrad, R., Gottschling, C., Leo, M., Faissner, A., & Wiese, S. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.02.007 · Cited by 48
“However, clinical trials using recombinant BDNF failed because of enzymatic degradation, poor delivery, and other limitations (Ochs et al., 2000; Thoenen and Sendtner, 2002).”
BackgroundPetrova, V., & Eva, R. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22608 · Cited by 43
“This seems to be the case for many growth factor receptors, as stimulation with NGF, BDNF, NT-3, NT-4, GDNF, has limited effects on CST regeneration (Thoenen and Sendtner, 2002; Kordower and Tuszynski, 2008).”
BackgroundCattaneo, A., & Capsoni, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.028 · Cited by 44
“The initial disappointing results obtained with neurotrophic factor therapies for different neurodegenerative diseases led to suggestions for “ improved methods for regulated local supply of NTs to specific populations of neurons “ (Thoenen and Sendtner 2002).”
Neurotrophic Factors in Neurodegenerative Disorders: Potential for Therapy
Fumagalli, F., Molteni, R., Calabrese, F., Maj, P. F., Racagni, G., & Riva, M. A. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00004 · Cited by 46
Downstream Consequences of Exercise Through the Action of BDNF
Sleiman, S. F., & Chao, M. V. (2015) · Brain Plasticity · doi:10.3233/bpl-150017 · Cited by 41
“However, many clinical trials have met with disappointing results, in part due to difficulties of delivery and unanticipated side effects [45].”
BackgroundКурахмаева, К. Б., Воронина, Т. А., Капица, И. Г., Kreuter, J., Неробкова, Л. Н., Середенин, С. Б., Балабаньян, В. Ю., & Alyautdin, R. N. (2008) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-008-0065-y · Cited by 41
Neurotrophins and Neurodegenerative Diseases: Receptors Stuck in Traffic?
Kruttgen, A., Saxena, S., Evangelopoulos, M. E., & Weis, J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.4.340 · Cited by 41
“Severe side effects were recorded especially in the case of CNTF application (94).”
BackgroundKeasey, M. P., Kang, S. S., Lovins, C., & Hagg, T. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-35 · Cited by 41
“Even so, clinical trials failed due to low penetration of CNTF into the CNS and systemic side effects after subcutaneous injections [14].”
BackgroundRole of Insulin-Like Growth Factors in Neuronal Plasticity and Neuroprotection
Torres‐Alemán, I. (2005) · Advances in experimental medicine and biology · doi:10.1007/0-387-26274-1_10 · Cited by 52
Adult Rat Spinal Cord Culture On An Organosilane Surface In A Novel Serum-Free Medium
Das, M., Bhargava, N., Gregory, C., Riedel, L., Molnar, P., & Hickman, J. J. (2005) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-005-0006-2 · Cited by 45
“…on the distribution of their receptors in the CNS and their therapeutic role in mammalian adult and embryonic spinal cord regeneration (Schnaar and Schaffner, 1981; Henderson et al., 1993; Hughes et al., 1993; Lindsay, 1994; Hanson et al., 1998; Henderson et al., 1998; Thoenen and Sendtner, 2002).”
BackgroundKato, R., Wolfe, D. P., Coyle, C. H., Huang, S., Wechuck, J., Goins, W. F., Krisky, D. M., Tsukamoto, T., Nelson, J. B., Glorioso, J. C., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302990 · Cited by 39
Nie, S., Ma, K., Sun, M., Lee, M., Yang, T., Chen, G., Zhang, Z., Zhang, Z., & Cao, X. (2019) · Parkinson s Disease · doi:10.1155/2019/9193534 · Cited by 41
Stroh, M., Zipfel, W. R., Williams, R. M., Chin, S. K., Webb, W. W., & Saltzman, W. M. (2004) · Nature Materials · doi:10.1038/nmat1159 · Cited by 39
“gif" NDATA ITEM> ]> Neurotrophins show promise in the treatment of neurodegenerative diseases; precise spatiotemporal control of exogenous neurotrophins in tissue is key to clinical succes”
BackgroundWatson, R. A., & Yeung, T. M. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-113 · Cited by 41
“Despite this, eliciting neural regrowth is an ambitious goal as despite early optimism, neurotrophin based therapies, which aim to induce a repair environment, have been largely unsuccessful [54-56] and harnessing this process has remained elusive.”
BackgroundZhang, L., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112075 · Cited by 41
Kato, R., Wolfe, D. P., Coyle, C. H., Wechuck, J., Tyagi, P., Tsukamoto, T., Nelson, J. B., Glorioso, J. C., Chancellor, M. B., & Yoshimura, N. (2008) · Gene Therapy · doi:10.1038/gt.2008.132 · Cited by 34
GDNF increases the survival of developing oculomotor neurons through a target-derived mechanism
Chen, J., Butowt, R., Rind, H. B., & von Bartheld, C. S. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00098-8 · Cited by 34
Therapy development in spinal muscular atrophy
Sendtner, M. (2010) · Nature Neuroscience · doi:10.1038/nn.2565 · Cited by 39
“Translation from mouse models to therapy: requirement for both new tools and validation In cell culture and mouse models of ALS, neurotrophic factors such as ciliary neurotrophic factor (CNTF), or other growth and differentiation factors, such as vascular endothelial factor (VEGF), can improve motor neuron survival, m…”
MethodSelf-citationRamburrun, P., Kumar, P., Choonara, Y. E., du Toit, L. C., & Pillay, V. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1266331 · Cited by 33
“eral nerve regeneration by promotion of neuronal survival, Schwann cell migration and axonal regeneration [5,6].”
BackgroundSampaio, T. B., Pinton, S., da Rocha, J. T., Gai, B. M., & Nogueira, C. W. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.054 · Cited by 37
“Although BDNF therapy elicits positive results on motor dysfunctions and neurodegeneration in animal models (Yoshimoto et al., 1995), the clinic trails with recombinant BDNF did not achieve success (Thoenen and Sendtner, 2002).”
Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Chu, T., & Wu, W. (2009) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152409787601914 · Cited by 35
Pérez‐Navarro, E., Canals, J. M., Ginés, S., & Alberch, J. (2006) · PubMed · doi:10.14670/hh-21.1217 · Cited by 44
Wiendl, H., & Kieseier, B. C. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.689 · Cited by 35
Ciliary neurotrophic factor is a key sex-specific regulator of depressive-like behavior in mice
Jia, C., Brown, R. W., Malone, H. M., Burgess, K. C., Gill, W. D., Keasey, M. P., & Hagg, T. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.09.038 · Cited by 34
“In a clinical trial, CNTF caused hyperalgesia, cramps and muscle pain (Thoenen and Sendtner, 2002), suggesting that the lack of CNTF may reduce pain sensitivity, possibly explaining why the foot-shock test revealed a reduced response.”
BackgroundTopical delivery of nerve growth factor for treatment of ocular and brain disorders
Eftimiadi, G., Soligo, M., Manni, L., Giuda, D. D., Calcagni, M. L., & Chiaretti, A. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306062 · Cited by 37
“However, large-scale clinical trials for central nervous system disorders have failed (Thoenen and Sendtner, 2002).”
BackgroundBiodistribution and brain permeability of the extracellular domain of neuregulin-1-β1
Rösler, T. W., Depboylu, C., Arias-Carrión, Ó., Woźny, W., Carlsson, T., Höllerhage, M., Oertel, W. H., Schrattenholz, A. S., & Höglinger, G. U. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.033 · Cited by 31
Depboylu, C., Höllerhage, M., Schnurrbusch, S., Brundin, P., Oertel, W. H., Schrattenholz, A. S., & Höglinger, G. U. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.10.050 · Cited by 36
Inhibition of astrocyte FAK–JNK signaling promotes subventricular zone neurogenesis through CNTF
Jia, C., Keasey, M. P., Lovins, C., & Hagg, T. (2018) · Glia · doi:10.1002/glia.23498 · Cited by 30
“2018;66:2456–2469. bioavailability and serious side effects of systemic administration of CNTF protein (Thoenen & Sendtner, 2002).”
BackgroundSaragovi, H. U., Galán, A., & Levin, L. A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00231 · Cited by 36
“…p75), their pleiotropic pro-survival and pro-death activities, short half-lives, poor pharmacokinetics and bioavailability (Yuen and Mobley, 1996; Thoenen and Sendtner, 2002), or because pro-death p75 receptors may be up-regulated in disease (Rudzinski et al., 2004; Ibanez and Simi, 2012), thus…”
BackgroundInfluentialNeurotrophic Factors and Neurodegenerative Diseases
Ruozi, B., Belletti, D., Bondioli, L., Vita, A. D., Forni, F., Vandelli, M. A., & Tosi, G. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00009-0 · Cited by 32
Protect, Repair, and Regenerate: Towards Restoring Vision in Glaucoma
Wareham, L. K., Risner, M. L., & Calkins, D. J. (2020) · Current Ophthalmology Reports · doi:10.1007/s40135-020-00259-5 · Cited by 32
ERRγ ligand HPB2 upregulates BDNF-TrkB and enhances dopaminergic neuronal phenotype
Kim, H. I., Lee, S., Lim, J., Chung, S.-K., Koo, T., Ji, Y.-G., Suh, Y., Son, W. S., Kim, S., & Choi, H. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105423 · Cited by 30
Anomal, R., de Villers-Sidani, E., Merzenich, M. M., & Panizzutti, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064208 · Cited by 28
“The observed effects of BDNF in A1 provide perspectives for the use of alternative therapies [34] in conjunction with cognitive training to improve the performance of language, reading and speech [16], [35], [36], [37].”
BackgroundMakar, T. K., Nimmagadda, V. K. C., Singh, I. S., Lam, K., Mubariz, F., Judge, S. I. V., Trisler, D. N., & Bever, C. T. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.01.002 · Cited by 32
“However, BDNF treatment has failed in clinical trials in neurodegenerative diseases (Thoenen and Sendtner, 2002) likely due to its short plasma half-life and poor blood brain barrier (BBB) penetration (Poduslo and Curran, 1996).”
BackgroundHaddad, Y., Adam, V., & Heger, Z. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00130 · Cited by 31
“, pain, particularly at the injection site) were noted early in clinical trials on neurodegenerative diseases (Thoenen and Sendtner, 2002).”
BackgroundMcLoon, L. K., Anderson, B. C., & Christiansen, S. P. (2006) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2006.06.011 · Cited by 29
“However, high-dose systemic administration has been associated with more side effects than therapeutic relief.(17) The use of sustained release of IGF-1 through implantable pellets resulted in significant increases in mean myofiber crosssectional area in the EOM, the duration of which can be controlled by pellet manuf…”
BackgroundZagrebelsky, M., & Körte, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374138 · Cited by 30
Arnold, S. A., & Hagg, T. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.047 · Cited by 32
“This would also circumvent the peripheral side effects and low bioavailability seen with systemic administration of CNTF (Thoenen and Sendtner, 2002).”
BackgroundHe, X., Yang, S., Zhang, R., Hou, L., Xu, J., Hu, Y., Xu, R., Wang, H., & Zhang, Y. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00018 · Cited by 27
“, 2013), unfortunately owing to large polypeptide structure and consequent poor oral bioavailability of exogenous BDNF, in clinical studies using BDNF as a therapeutic agent have been inconclusive (Thoenen and Sendtner, 2002).”
BackgroundSignaling by Neuronal Tyrosine Kinase Receptors: Relevance for Development and Regeneration
Hausott, B., Kurnaz, I. A., Gajović, S., & Klimaschewski, L. P. (2009) · The Anatomical Record · doi:10.1002/ar.20964 · Cited by 30
“However, early clinical trials with neurotrophins given to patients with neurodegenerative diseases did not fulfill the promise (Thoenen and Sendtner, 2002).”
BackgroundAteaque, S., Merkouris, S., Wyatt, S. L., Allen, N. D., Xie, J., DiStefano, P. S., Lindsay, R. M., & Barde, Y. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15617 · Cited by 26
“Our observations suggest that, compared to several studies conducted in the past, the use of much lower concentrations of Trk agonists may lead to more robust outcomes than has been observed in the past when using neurotrophins to treat neurodegenerative conditions (Thoenen & Sendtner, 2002).”
ResultZassler, B., & Humpel, C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.009 · Cited by 28
Neuro-Immune Crosstalk in CNS Diseases
Kerschensteiner, M., Meinl, E., & Hohlfeld, R. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2009_6 · Cited by 28
Induction of Neurorestoration from Endogenous Stem Cells
Yu, J. H., Seo, J. H., Lee, J. Y., Lee, M.-Y., & Cho, S. (2016) · Cell Transplantation · doi:10.3727/096368916x690511 · Cited by 27
Bradshaw, R. A., Mobley, W. C., & Rush, R. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061143 · Cited by 27
Recognition of cellular implants by the brain's innate immune system
Bergwerf, I., Tambuyzer, B. R., Vocht, N. D., Reekmans, K., Praet, J., Daans, J., Chatterjee, S., Pauwels, P., der Linden, A. V., Berneman, Z. N., et al. (2010) · Immunology and Cell Biology · doi:10.1038/icb.2010.141 · Cited by 27
TrkAIn VivoFunction Is Negatively Regulated by Ubiquitination
Kiris, E., Wang, T. Z., Yanpallewar, S. U., Dorsey, S. G., Becker, J., Bavari, S., Palko, M. E., Coppola, V., & Tessarollo, L. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4294-13.2014 · Cited by 27
“So far, this effort has not been successful partly due to the still insufficient knowledge of the mechanisms controlling the activity of these ligand/receptor systems (Thoenen and Sendtner, 2002).”
BackgroundYang, W., Chen, Z., Ma, X., Ouyang, X., Fang, J., & Wei, H. (2020) · Cell Proliferation · doi:10.1111/cpr.12756 · Cited by 24
Zuo, L., Dai, C., Yi, L., & Dong, Z. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00643-5 · Cited by 24
Membrane turnover and receptor trafficking in regenerating axons
Hausott, B., & Klimaschewski, L. P. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.13025 · Cited by 27
“The neurotrophins activate specific tropomyosin receptor kinases, i.e. TrkA, TrkB, and TrkC.”
BackgroundInfluentialChian, R.-J., Li, J., Ay, İ., Celia, S. A., Kashi, B. B., Tamrazian, E., Matthews, J. C., Bronson, R. T., Rossomando, A. J., Pepinsky, R. B., et al. (2009) · Brain Research · doi:10.1016/j.brainres.2009.06.066 · Cited by 27
Current prospects and challenges for epilepsy gene therapy
Weinberg, M. S., & McCown, T. J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.003 · Cited by 25
“Neurotrophic Factors Neurotrophic factors (NTFs) and their receptors have long been considered important molecules involved in brain injury and repair (Abe, 2000), and are thought to be key mediators of both synaptic plasticity (Schinder and Poo, 2000) and the changes associated Exp Neurol.”
BackgroundPolymeric Systems for Bioinspired Delivery of Angiogenic Molecules
Fischbach, C., & Mooney, D. J. (2006) · Springer eBooks · doi:10.1007/12_070 · Cited by 30
Anterograde Transport of Neurotrophic Factors: Possible Therapeutic Implications
Caleo, M., & Cenni, M. C. (2004) · Molecular Neurobiology · doi:10.1385/mn:29:2:179 · Cited by 26
“In this respect, it is hoped that their survival-promoting effects may be exploited for the development of novel therapeutic approaches for the treatment of neurodegenerative conditions (11,12).”
BackgroundLi, Y., Liu, Y., Li, X., Ji, Y., Yang, X., Hang, X.-T., Ding, Z., Liu, F., Wang, Y., & Shen, A. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9049-2 · Cited by 25
Gupta, V., Chitranshi, N., Gupta, V., You, Y., Rajput, R., Paulo, J. A., Mirzaei, M., van den Buuse, M., & Graham, S. L. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.01.020 · Cited by 24
Atluri, V. S. R., Jayant, R. D., Pilakka‐Kanthikeel, S., Garcia, G., Samikkannu, T., Yndart, A., Kaushik, A. K., & Nair, M. G. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s108329 · Cited by 23
“In clinical trials, systemic side effects are the limiting factors observed while delivering the optimum doses that have therapeutic effects within the brain.(34) It is necessary to develop innovative technologies to deliver various neurotropic factors across the BBB to reduce the neurotoxic effects observed in variou…”
Yu, Q., Chang, Q., Liu, X., Gong, S., Ye, K., & Lin, X. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.154 · Cited by 25
“Presumably, this is due to poor delivery and the short in vivo half-life of BDNF [6].”
Background
Metadata
- Authors
- Thoenen, H., & Sendtner, M.
- Affiliations
- Max Planck Society (DE)
- University of Würzburg (DE)
- ORCID
- Sendtner, Michael
- Venue
- Nature Neuroscience
- Published
- 2002-10-28
- Volume
- 5
- Issue
- S11
- Pages
- 1046-1050
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2058026578
- Cited by
- 336
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 19 · 2018: 9 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 10 · 2013: 17 · 2012: 17
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Eli Lilly and Company
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- neurotrophins, neurotrophic factors, clinical trials, treatment failure, neurotrophin receptors, signal transduction, gene therapy
- MeSH terms
- Animals, Central Nervous System Diseases, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Humans, Nerve Growth Factors, Peripheral Nervous System Diseases, Drug Design, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.